Literature DB >> 27652332

Maybe we don't know JAK?

Luis J Schwarz1, Justin M Balko2.   

Abstract

The cornerstone for precision medicine is the development of robust biomarkers that reflect molecular phenotypes and therapeutic vulnerabilities in disease. We recently described Janus kinase-2 (JAK2)-specific inhibition as a therapeutic opportunity in triple negative breast cancers with 9p24 amplification. Here, we comment on this work and discuss the challenges of targeting this amplicon.

Entities:  

Keywords:  9p24; JAK2; PD-L1; breast cancer; chemotherapy

Year:  2016        PMID： 27652332      PMCID： PMC4972112          DOI： 10.1080/23723556.2016.1192713

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

1.  Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent.

Authors:  Rita Andraos; Zhiyan Qian; Débora Bonenfant; Joëlle Rubert; Eric Vangrevelinghe; Clemens Scheufler; Fanny Marque; Catherine H Régnier; Alain De Pover; Hugues Ryckelynck; Neha Bhagwat; Priya Koppikar; Aviva Goel; Lorenza Wyder; Gisele Tavares; Fabienne Baffert; Carole Pissot-Soldermann; Paul W Manley; Christoph Gaul; Hans Voshol; Ross L Levine; William R Sellers; Francesco Hofmann; Thomas Radimerski
Journal:  Cancer Discov       Date:  2012-05-03       Impact factor: 39.397

2.  Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?

Authors:  Annkristin Heine; Peter Brossart; Dominik Wolf
Journal:  Blood       Date:  2013-11-28       Impact factor: 22.113

3.  CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.

Authors:  Sara C Meyer; Matthew D Keller; Sophia Chiu; Priya Koppikar; Olga A Guryanova; Franck Rapaport; Ke Xu; Katia Manova; Dmitry Pankov; Richard J O'Reilly; Maria Kleppe; Anna Sophia McKenney; Alan H Shih; Kaitlyn Shank; Jihae Ahn; Eftymia Papalexi; Barbara Spitzer; Nick Socci; Agnes Viale; Emeline Mandon; Nicolas Ebel; Rita Andraos; Joëlle Rubert; Ernesta Dammassa; Vincent Romanet; Arno Dölemeyer; Michael Zender; Melanie Heinlein; Raajit Rampal; Rona Singer Weinberg; Ronald Hoffman; William R Sellers; Francesco Hofmann; Masato Murakami; Fabienne Baffert; Christoph Gaul; Thomas Radimerski; Ross L Levine
Journal:  Cancer Cell       Date:  2015-07-13       Impact factor: 31.743

4.  Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Authors:  Michael R Green; Stefano Monti; Scott J Rodig; Przemyslaw Juszczynski; Treeve Currie; Evan O'Donnell; Bjoern Chapuy; Kunihiko Takeyama; Donna Neuberg; Todd R Golub; Jeffery L Kutok; Margaret A Shipp
Journal:  Blood       Date:  2010-07-13       Impact factor: 22.113

5.  STAT5 Is a Key Regulator in NK Cells and Acts as a Molecular Switch from Tumor Surveillance to Tumor Promotion.

Authors:  Dagmar Gotthardt; Eva M Putz; Eva Grundschober; Michaela Prchal-Murphy; Elisabeth Straka; Petra Kudweis; Gerwin Heller; Zsuzsanna Bago-Horvath; Agnieszka Witalisz-Siepracka; Abbarna A Cumaraswamy; Patrick T Gunning; Birgit Strobl; Mathias Müller; Richard Moriggl; Christian Stockmann; Veronika Sexl
Journal:  Cancer Discov       Date:  2016-02-12       Impact factor: 39.397

6.  Cooperative epigenetic modulation by cancer amplicon genes.

Authors:  Lixin Rui; N C Tolga Emre; Michael J Kruhlak; Hye-Jung Chung; Christian Steidl; Graham Slack; George W Wright; Georg Lenz; Vu N Ngo; Arthur L Shaffer; Weihong Xu; Hong Zhao; Yandan Yang; Laurence Lamy; R Eric Davis; Wenming Xiao; John Powell; David Maloney; Craig J Thomas; Peter Möller; Andreas Rosenwald; German Ott; Hans Konrad Muller-Hermelink; Kerry Savage; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Dennis D Weisenburger; Wing C Chan; Randy D Gascoyne; David Levens; Louis M Staudt
Journal:  Cancer Cell       Date:  2010-12-14       Impact factor: 31.743

7.  PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.

Authors:  Margaretha G M Roemer; Ranjana H Advani; Azra H Ligon; Yasodha Natkunam; Robert A Redd; Heather Homer; Courtney F Connelly; Heather H Sun; Sarah E Daadi; Gordon J Freeman; Philippe Armand; Bjoern Chapuy; Daphne de Jong; Richard T Hoppe; Donna S Neuberg; Scott J Rodig; Margaret A Shipp
Journal:  J Clin Oncol       Date:  2016-04-11       Impact factor: 44.544

8.  Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence.

Authors:  Justin M Balko; Luis J Schwarz; Na Luo; Mónica V Estrada; Jennifer M Giltnane; Daniel Dávila-González; Kai Wang; Violeta Sánchez; Phillip T Dean; Susan E Combs; Donna Hicks; Joseph A Pinto; Melissa D Landis; Franco D Doimi; Roman Yelensky; Vincent A Miller; Phillip J Stephens; David L Rimm; Henry Gómez; Jenny C Chang; Melinda E Sanders; Rebecca S Cook; Carlos L Arteaga
Journal:  Sci Transl Med       Date:  2016-04-13       Impact factor: 17.956

9.  Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo.

Authors:  Yansheng Hao; Bjoern Chapuy; Stefano Monti; Heather H Sun; Scott J Rodig; Margaret A Shipp
Journal:  Clin Cancer Res       Date:  2014-03-07       Impact factor: 12.531

10.  Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer.

Authors:  Michael T Barrett; Karen S Anderson; Elizabeth Lenkiewicz; Mariacarla Andreozzi; Heather E Cunliffe; Christine L Klassen; Amylou C Dueck; Ann E McCullough; Srikanth K Reddy; Ramesh K Ramanathan; Donald W Northfelt; Barbara A Pockaj
Journal:  Oncotarget       Date:  2015-09-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.